Skip to main content
AAN.com
At the time of this writing, healthcare systems are facing worldwide the pandemic of the coronavirus severe acute respiratory coronavirus 2 (SARS-COV-2) and its associated disease, named cronavirus disease 19 (COVID-19). This virus is a new human pathogen, and currently, there are no specific treatment options.1 COVID-19 mostly affects the respiratory system, ranging from mild flu-like symptoms to severe pneumonia, but extrarespiratory multisystemic involvement has also been reported.2 Li et al.3 recently described the neuroinvasive potential of COVID-19, but, to our knowledge, no case of acute dysimmune neuropathy has been described so far. Here, the authors report the case of an acute and severe peripheral nervous system disorder possibly related to COVID-19 infection.
A 71-year-old male patient was referred to the emergency department for subacute onset of paresthesia at limb extremities, followed by distal weakness rapidly evolving to a severe, flaccid tetraparesis over the previous 3 days. In the previous week, he had low grade fever for a few days. Relevant conditions at his medical history included hypertension, abdominal aortic aneurysm treated with endovascular repair in 2017, and lung cancer treated with surgery only (without additional chemotherapy or radiotherapy) in 2017 with negative oncological follow-up; no previous neurologic history was reported. Neurologic examination showed normal consciousness and language, no cranial nerve deficit, symmetric limb weakness (Medical Research Council score 3/5 at upper limbs and 2/5 at lower limbs), symmetric and extensive stocking-and-glove hypesthesia at the 4 limbs (more pronounced at lower limbs), absent deep tendon reflexes, and normal plantar response. The patients complained of severe paresthesia in both hands and feet. Moderate dyspnea and moderate low back pain were present at the time of the first evaluation. He showed hemodynamic disturbances with severe drug-resistant hypertension. Arterial blood gases indicated severe hypoxia (paO2 65 mm Hg without supplemental oxygen). Brain CT scan was normal, whereas chest CT scan showed multiple bilateral ground glass opacities and consolidations, typical of COVID-19 pneumonia. Nasopharyngeal swab tested positive for SARS-CoV-2. Lumbar puncture was performed urgently and showed a mild increase in the protein content (54 mg/dL) and mild leukocytosis (9 cells/μL); CSF was negative for SARS-CoV-2. Electroneurography showed the absence of both the sural nerve sensory nerve action potential (SAP) and the tibial nerve compound muscle action potential (CMAP), markedly increased common peroneal CMAP distal latency, markedly decreased velocity, moderately decreased CMAP amplitude (with spatial and temporal dispersion) for the same nerve, and decreased ulnar SAP amplitude. F waves were not performed at lower limbs for the reduced amplitude of the evocable CMAP and not performed at upper limbs for intolerance at the stimulation. See table for a summary of nerve conduction studies results.
Table Nerve conduction study parameters
Overall, these findings were interpreted as a severe form of acute polyradiculoneuritis with prominent demyelinating features. Diagnosis of Guillain-Barré syndrome (GBS) associated with COVID-19 was made. High-dose IV immunoglobulins (0.4 g/kg/d for 5 days) were started few hours after admission, together with high-flow 60%–80% oxygen via nonrebreather mask, antiviral therapy (lopinavir + ritonavir), and hydroxychloroquine. Despite these efforts, severe respiratory failure developed during the first 24 hours after admission, unresponsive to continuous positive airway pressure ventilation and prone positioning. The patient died a few hours later because of progressive respiratory failure.
The authors report a possible correlation between acute COVID-19 infection and GBS, a condition that in recent years has been linked to other emergent infections, such as Zika virus.4 Our case suggests that COVID-19 may cause peripheral nervous system involvement, even before the resolution of pneumonia, meeting the diagnostic criteria of an acute sensory and motor polyradiculoneuritis. Dysregulation of the immune system due to COVID-19 is not that surprising because McGonagle et al.5 recently described systemic hyperinflammation in COVID-19 patients with a macrophage activation syndrome, also known as secondary hemophagocytic lymphohistiocytosis; notably, Quin et al.6 also retrospectively evaluated a cohort of 452 patients with COVID-19 observing alterations in lymphocytes.
Early respiratory support, including ICU admission, is indicated but not always feasible during the current pandemic.
The authors agree that a close attention to neurologic complications of COVID-19 is needed, as recently suggested by Mao et al.7 The Italian Society of Neurology is currently proposing a multicenter nationwide observational study on neurologic presentations and complications of COVID-19. Similar efforts by other neurologic societies worldwide will benefit both neurologists and patients at a global level.

Acknowledgment

We thank Giuseppina Resta for her technical assistance for nerve conduction studies.

Appendix Authors

References

1.
Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest 2020;130:1545–1548.
2.
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–1069.
3.
Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 2020;92:552–555.
4.
Krauer F, Riesen M, Reveiz L, et al. Zika virus infection as a cause of congenital brain abnormalities and Guillain-barré syndrome: systematic review. PLoS Med 2017;14:e1002203.
5.
McGonagle D, Sharif K, O'Regan A, et al. Interleukin-6 use in COVID-19 pneumonia related macrophage activation syndrome. Autoimmun Rev 2020:102537.
6.
Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis Epub 2020 Mar 12.
7.
Mao L, Wang M, Chen S et al. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. Available at: https://doi.org/10.1101/2020.02.22.20026500. Accessed March 28, 2020.
Letters to the Editor
20 May 2020
RE: Guillain-Barre Syndrome Related to COVID-19 Infection. Comments after 16 published cases
Cristina Guijarro-Castro, Neurologist. School of Medicine Professor| CINAC Puerta del Sur

We read with interest the paper by Alberti et al.1 We want to comment on a similar Guillain- Barré Syndrome (GBS) case following bilateral SARS-CoV2 pneumonia and to highlight the evolution of post-infectious GBS.

On May 4th, 2020, a 70-year-old man presented with progressive weakness of all limbs of 5 days of progression, after SARS-CoV-2 infection two weeks before.

Neurologic examination showed asymmetric weakness (Medical Research Council grade 4/5, right hand; 4+/5, left hand; 4/5, left leg and 3+/5, right leg) and areflexia in both legs and feet. Nerve conduction studies (day 6) exhibited delayed distal latencies and absent F waves in early course and albumin-cytological dissociation in CSF. He was diagnosed with GBS and IV immunoglobulins (0.4 g/kg/d for 5 days) were started 8 hours after admission. He evolved favorably and was discharged with minimum deficit.

To date and to our knowledge, three prior cases of GBS concomitant with SARS-CoV-2 infection and a parainfectious profile have been reported1,2,3 and thirteen after SARS-CoV-2 infection2,4 (Table 1). These cases support a causal relationship with SARS-CoV-2 infection.

The Spanish Society of Neurology develops a multicenter nationwide observational study on neurologic presentations and complications of COVID-19.

Disclosure

For disclosures, please contact the editorial office at [email protected].

References

  1. Alberti P, Beretta S, Piatti M, et al. Guillain-Barré syndrome related to COVID-19 infection. Neurol Neuroimmunol Neuroinflamm 2020;7:e741.
  2. Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol 2020;19:383–384.
  3. Galán AV, Saucedo PDS, Postigo FP, Paniagua EB. Guillain-Barré Syndrome Associated With SARS-CoV-2 Infection. Neurologia 2020; S0213-4853:30072-4.
  4. Toscano G, Palmerini F, Ravaglia S, et al. Guillain–Barré Syndrome Associated with SARS-CoV-2. N Engl J Med 2020 Epub Apr 17.

Information & Authors

Information

Published In

Neurology® Neuroimmunology & Neuroinflammation
Volume 7Number 4July 2020
PubMed: 32350026

Publication History

Received: April 2, 2020
Accepted: April 13, 2020
Published online: April 29, 2020
Published in print: July 2020

Permissions

Request permissions for this article.

Disclosure

The authors have nothing to disclose. Go to Neurology.org/NN for full disclosures.

Study Funding

This study was supported by the Italian Ministry of University and Research grant PRIN 2017CY3J3W.

Authors

Affiliations & Disclosures

From the Department of Neurology (P.A., S.B., M.P., A.K., M.L.P., P.S., M.V., G.G., F.P., D.A.M., I.A., C.F.), San Gerardo Hospital, ASST Monza, University of Milano Bicocca, Monza, Italy; School of Medicine and Surgery (P.A., S.B., M.P., A.K., M.V., G.G., F.P., D.A.M., I.A., C.F.), University of Milano-Bicocca, Monza, Italy; and NeuroMi (Milan Center for Neuroscience) (P.A., S.B., I.A., C.F.), Milan, Italy.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Simone Beretta, MD, PhD*
From the Department of Neurology (P.A., S.B., M.P., A.K., M.L.P., P.S., M.V., G.G., F.P., D.A.M., I.A., C.F.), San Gerardo Hospital, ASST Monza, University of Milano Bicocca, Monza, Italy; School of Medicine and Surgery (P.A., S.B., M.P., A.K., M.V., G.G., F.P., D.A.M., I.A., C.F.), University of Milano-Bicocca, Monza, Italy; and NeuroMi (Milan Center for Neuroscience) (P.A., S.B., I.A., C.F.), Milan, Italy.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Associated Editor, Frontiers in Neurology, from May 2019, I do not received compansation
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Marco Piatti, MD
From the Department of Neurology (P.A., S.B., M.P., A.K., M.L.P., P.S., M.V., G.G., F.P., D.A.M., I.A., C.F.), San Gerardo Hospital, ASST Monza, University of Milano Bicocca, Monza, Italy; School of Medicine and Surgery (P.A., S.B., M.P., A.K., M.V., G.G., F.P., D.A.M., I.A., C.F.), University of Milano-Bicocca, Monza, Italy; and NeuroMi (Milan Center for Neuroscience) (P.A., S.B., I.A., C.F.), Milan, Italy.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Aristotelis Karantzoulis, MD
From the Department of Neurology (P.A., S.B., M.P., A.K., M.L.P., P.S., M.V., G.G., F.P., D.A.M., I.A., C.F.), San Gerardo Hospital, ASST Monza, University of Milano Bicocca, Monza, Italy; School of Medicine and Surgery (P.A., S.B., M.P., A.K., M.V., G.G., F.P., D.A.M., I.A., C.F.), University of Milano-Bicocca, Monza, Italy; and NeuroMi (Milan Center for Neuroscience) (P.A., S.B., I.A., C.F.), Milan, Italy.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Maria Luisa Piatti, MD
From the Department of Neurology (P.A., S.B., M.P., A.K., M.L.P., P.S., M.V., G.G., F.P., D.A.M., I.A., C.F.), San Gerardo Hospital, ASST Monza, University of Milano Bicocca, Monza, Italy; School of Medicine and Surgery (P.A., S.B., M.P., A.K., M.V., G.G., F.P., D.A.M., I.A., C.F.), University of Milano-Bicocca, Monza, Italy; and NeuroMi (Milan Center for Neuroscience) (P.A., S.B., I.A., C.F.), Milan, Italy.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Patrizia Santoro, MD
From the Department of Neurology (P.A., S.B., M.P., A.K., M.L.P., P.S., M.V., G.G., F.P., D.A.M., I.A., C.F.), San Gerardo Hospital, ASST Monza, University of Milano Bicocca, Monza, Italy; School of Medicine and Surgery (P.A., S.B., M.P., A.K., M.V., G.G., F.P., D.A.M., I.A., C.F.), University of Milano-Bicocca, Monza, Italy; and NeuroMi (Milan Center for Neuroscience) (P.A., S.B., I.A., C.F.), Milan, Italy.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Martina Viganò, MD
From the Department of Neurology (P.A., S.B., M.P., A.K., M.L.P., P.S., M.V., G.G., F.P., D.A.M., I.A., C.F.), San Gerardo Hospital, ASST Monza, University of Milano Bicocca, Monza, Italy; School of Medicine and Surgery (P.A., S.B., M.P., A.K., M.V., G.G., F.P., D.A.M., I.A., C.F.), University of Milano-Bicocca, Monza, Italy; and NeuroMi (Milan Center for Neuroscience) (P.A., S.B., I.A., C.F.), Milan, Italy.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Ginevra Giovannelli, MD
From the Department of Neurology (P.A., S.B., M.P., A.K., M.L.P., P.S., M.V., G.G., F.P., D.A.M., I.A., C.F.), San Gerardo Hospital, ASST Monza, University of Milano Bicocca, Monza, Italy; School of Medicine and Surgery (P.A., S.B., M.P., A.K., M.V., G.G., F.P., D.A.M., I.A., C.F.), University of Milano-Bicocca, Monza, Italy; and NeuroMi (Milan Center for Neuroscience) (P.A., S.B., I.A., C.F.), Milan, Italy.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Fiammetta Pirro, MD
From the Department of Neurology (P.A., S.B., M.P., A.K., M.L.P., P.S., M.V., G.G., F.P., D.A.M., I.A., C.F.), San Gerardo Hospital, ASST Monza, University of Milano Bicocca, Monza, Italy; School of Medicine and Surgery (P.A., S.B., M.P., A.K., M.V., G.G., F.P., D.A.M., I.A., C.F.), University of Milano-Bicocca, Monza, Italy; and NeuroMi (Milan Center for Neuroscience) (P.A., S.B., I.A., C.F.), Milan, Italy.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Danilo Antonio Montisano, MD
From the Department of Neurology (P.A., S.B., M.P., A.K., M.L.P., P.S., M.V., G.G., F.P., D.A.M., I.A., C.F.), San Gerardo Hospital, ASST Monza, University of Milano Bicocca, Monza, Italy; School of Medicine and Surgery (P.A., S.B., M.P., A.K., M.V., G.G., F.P., D.A.M., I.A., C.F.), University of Milano-Bicocca, Monza, Italy; and NeuroMi (Milan Center for Neuroscience) (P.A., S.B., I.A., C.F.), Milan, Italy.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Ildebrando Appollonio, MD
From the Department of Neurology (P.A., S.B., M.P., A.K., M.L.P., P.S., M.V., G.G., F.P., D.A.M., I.A., C.F.), San Gerardo Hospital, ASST Monza, University of Milano Bicocca, Monza, Italy; School of Medicine and Surgery (P.A., S.B., M.P., A.K., M.V., G.G., F.P., D.A.M., I.A., C.F.), University of Milano-Bicocca, Monza, Italy; and NeuroMi (Milan Center for Neuroscience) (P.A., S.B., I.A., C.F.), Milan, Italy.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Carlo Ferrarese, MD, PhD
From the Department of Neurology (P.A., S.B., M.P., A.K., M.L.P., P.S., M.V., G.G., F.P., D.A.M., I.A., C.F.), San Gerardo Hospital, ASST Monza, University of Milano Bicocca, Monza, Italy; School of Medicine and Surgery (P.A., S.B., M.P., A.K., M.V., G.G., F.P., D.A.M., I.A., C.F.), University of Milano-Bicocca, Monza, Italy; and NeuroMi (Milan Center for Neuroscience) (P.A., S.B., I.A., C.F.), Milan, Italy.
Disclosure
Scientific Advisory Boards:
1.
Scientific Advisory Board of Gantenerumab Study (Roche) Scientific Advisory Board of Merck Scientific Advisory Board od DOC Scientific Advisory Board of Biogen
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Travel reimbursement from Roche to attend Advisory Board of Gatenerumab in San Diego (Nov. 2013) Travel reimbursement from Merck to attend Advisory Board (Rome, March 2018)
Editorial Boards:
1.
Member of editorial board of Neurological Sciences since 2011. No compensation Associate Editor of Parkinson Disease (no compensation)
Patents:
1.
NONE
Publishing Royalties:
1.
Textbook: Malattie del sistema nervoso, McGraw Hill, 2016
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
1. Roche 2. Merck 3. Biogen 4. DOC
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence Dr. Alberti [email protected]
*
These authors equally contributed to the paper.
The Article Processing Charge was funded by the authors.
Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. iPSC ‐derived human cortical organoids display profound alterations of cellular homeostasis following SARS ‐ CoV ‐2 infection and Spike protein exposure , The FASEB Journal, 39, 4, (2025).https://doi.org/10.1096/fj.202401604RRR
    Crossref
  2. COVID-19: Unveiling the Neuropsychiatric Maze—From Acute to Long-Term Manifestations, Biomedicines, 12, 6, (1147), (2024).https://doi.org/10.3390/biomedicines12061147
    Crossref
  3. Visual evoked potential abnormalities in patients with COVID-19, Revista da Associação Médica Brasileira, 70, 2, (2024).https://doi.org/10.1590/1806-9282.20231061
    Crossref
  4. Guillain-Barré Syndrome Following Lumbar Spine Surgery: A Case Report Highlighting Early Magnetic Resonance Neurography Findings, HSS Journal®: The Musculoskeletal Journal of Hospital for Special Surgery, (2024).https://doi.org/10.1177/15563316241294049
    Crossref
  5. The National Institutes of Health COVID-19 Neuro Databank/Biobank: Creation and Evolution, Neuroepidemiology, (1-13), (2024).https://doi.org/10.1159/000539830
    Crossref
  6. A nationwide Guillain–Barré syndrome epidemiological study in Spain during the COVID ‐19 years , European Journal of Neurology, 31, 12, (2024).https://doi.org/10.1111/ene.16439
    Crossref
  7. Successful treatment with plasmapheresis of severe Bickerstaff brainstem encephalitis with high cerebrospinal fluid CXCL ‐10 levels after COVID ‐19 infection: A case report , Clinical and Experimental Neuroimmunology, (2024).https://doi.org/10.1111/cen3.12806
    Crossref
  8. Neurologische Langzeitfolgen von COVID-19, Fortschritte der Neurologie · Psychiatrie, 92, 09, (362-377), (2024).https://doi.org/10.1055/a-2335-0198
    Crossref
  9. Neurologische Langzeitfolgen von COVID-19, Neurologie up2date, 07, 01, (45-63), (2024).https://doi.org/10.1055/a-1927-4006
    Crossref
  10. Insights Into MRI Neuroimaging Patterns of COVID-19 in Children: A Retrospective Comprehensive Analysis, Academic Radiology, 31, 6, (2536-2549), (2024).https://doi.org/10.1016/j.acra.2024.03.018
    Crossref
  11. See more
Loading...

View Options

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text
Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

Figures

Tables

Media

Share

Share

Share article link

Share